Challenging Issues in Clinical Trial Design Part 4 of a 4-Part Series on Statistics for Clinical Trials

Journal of the American College of Cardiology

Volumn 66, Issue 25, 2015, Pages 2886-2898

  Pocock, Stuart J ^a   Clayton, Tim C ^a   Stone, Gregg W ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Department of Medicine   (United States)

Author keywords

adaptive designs; Data Monitoring Committees; factorial designs; noninferiority trials; randomized controlled trials as topic; statistical stopping guidelines; strategy trials

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CANGRELOR; CAPTOPRIL; CLOPIDOGREL; DRONEDARONE; ENALAPRIL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; IVABRADINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; SACUBITRIL PLUS VALSARTAN; TORCETRAPIB;

ACUTE CORONARY SYNDROME; ANEMIA; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BARE METAL STENT; CARDIOLOGY; CLINICAL TRIAL (TOPIC); DRUG MEGADOSE; FACTORIAL DESIGN; HEART FAILURE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; PACLITAXEL ELUTING CORONARY STENT; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; REVIEW; SAMPLE SIZE; STATISTICS; PROCEDURES; STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA;

CARDIOLOGY; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; DATA INTERPRETATION, STATISTICAL; GUIDELINES AS TOPIC; HUMANS;

EID: 84955454921     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.10.051     Document Type: Review

References (63)

1. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: non-inferiority clinical trials. Draft guidance. 2010. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm202140.pdf. Accessed November 2, 2015.
2. G. Piaggio, D.R. Elbourne, S.J. Pocock, et al. for the CONSORT Group Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement JAMA 308 2012 2594 2604
3. S.M. Mulla, I.A. Scott, C.A. Jackevicius, and et al. How to use a noninferiority trial: users' guides to the medical literature JAMA 308 2012 2605 2611
4. J.H. Ware, and E.M. Antman Equivalence trials N Engl J Med 337 1997 1159 1161
5. G.W. Stone, B.T. McLaurin, D.A. Cox, et al. for the ACUITY Investigators Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216
6. M.J. Brown, C.R. Palmer, A. Castaigne, and et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) Lancet 356 2000 366 372
7. F. Feres, R.A. Costa, A. Abizaid, et al. for the OPTIMIZE Trial Investigators Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 2013 2510 2522
8. H.R. Black, W.J. Elliott, G. Grandits, et al. for the CONVINCE Research Group Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial JAMA 289 2003 2073 2082
9. G.W. Stone, C. Rogers, J. Hermiller, et al. for the FilterWire EX Randomized Evaluation (FIRE) Investigators Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts Circulation 108 2003 548 553
10. Hoffman-LaRoche. A study of roactemra/actemra (tocilizumab) in comparison to etanercept in patients with rheumatoid arthritis and cardiovascular disease risk factors. 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT01331837. Accessed November 2, 2015.
11. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Accessed November 2, 2015.
12. B. Zinman, C. Wanner, J.M. Lachin, and et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2015 2117 2128
13. A.A. Montgomery, T.J. Peters, and P. Little Design, analysis and presentation of factorial randomised controlled trials BMC Med Res Methodol 3 2003 26
14. J. Lubsen, and S. Pocock Factorial trials in cardiology: pros and cons Eur Heart J 15 1994 585 588
15. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
16. Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients N Engl J Med 342 2000 154 160
17. CURRENT-OASIS 7 Investigators Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
18. G.W. Stone, B. Witzenbichler, G. Guagliumi, et al. for the HORIZONS-AMI Trial Investigators Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
19. G.W. Stone, A.J. Lansky, S.J. Pocock, et al. for the HORIZONS-AMI Trial Investigators Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction N Engl J Med 360 2009 1946 1959
20. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction Lancet 345 1995 669 685
21. M. Valgimigli, E. Frigoli, S. Leonardi, et al. for the MATRIX Investigators Bivalirudin or unfractionated heparin in acute coronary syndromes N Engl J Med 373 2015 997 1009
22. M. Valgimigli, A. Gagnor, P. Calabró, et al. for the MATRIX Investigators Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial Lancet 385 2015 2465 2476
23. S.R. Tunis, D.B. Stryer, and C.M. Clancy Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy JAMA 290 2003 1624 1632
24. S.J. Pocock, and B.J. Gersh Do current clinical trials meet society's needs? A critical review of recent evidence J Am Coll Cardiol 64 2014 1615 1628
25. New York University School of Medicine. International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA). 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT01471522. Accessed November 2, 2015.
26. G.W. Stone, J.S. Hochman, D.O. Williams, and et al. Medical therapy with versus without routine revascularization in patients with stable ischemic heart disease and moderate or severe ischemia: the case for community equipoise J Am Coll Cardiol 67 2016 81 99
27. D.J. Maron, G.W. Stone, D.S. Berman, and et al. Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists Am Heart J 162 2011 1034 1043.e13
28. C.R. Smith, M.B. Leon, M.J. Mack, et al. for the PARTNER Trial Investigators Transcatheter versus surgical aortic-valve replacement in high-risk patients N Engl J Med 364 2011 2187 2198
29. D.H. Adams, J.J. Popma, M.J. Reardon, et al. for the U.S. CoreValve Clinical Investigators Transcatheter aortic-valve replacement with a self-expanding prosthesis N Engl J Med 370 2014 1790 1798
30. W.E. Boden, R.A. O'Rourke, K.K. Teo, et al. for the COURAGE Trial Research Group Optimal medical therapy with or without PCI for stable coronary disease N Engl J Med 356 2007 1503 1516
31. P.W. Serruys, M.C. Morice, A.P. Kappetein, et al. for the SYNTAX Investigators Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease [Erratum in N Engl J Med 2013;368:584] N Engl J Med 360 2009 961 972
32. T. Palmerini, U. Benedetto, G. Biondi-Zoccai, and et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis J Am Coll Cardiol 65 2015 2496 2507
33. S. Windecker, S. Stortecky, G.G. Stefanini, and et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis BMJ 348 2014 g3859
34. S.J. Pocock, and D.R. Elbourne Randomized trials or observational tribulations? N Engl J Med 342 2000 1907 1909
35. M.L. Brown, B.J. Gersh, D.R. Holmes, and et al. From randomized trials to registry studies: translating data into clinical information Nat Clin Pract Cardiovasc Med 5 2008 613 620
36. B. Lagerqvist, O. Fröbert, G.K. Olivecrona, and et al. Outcomes 1 year after thrombus aspiration for myocardial infarction N Engl J Med 371 2014 1111 1120
37. S.S. Ellenberg, T.R. Fleming, and D.L. DeMets Data Monitoring Committees in Clinical Trials: A Practical Perspective 2003 John Wiley & Sons Chichester, England
38. F. Zannad, W. Gattis Stough, J.J.V. McMurray, and et al. When to stop a clinical trial early for benefit: lessons learned and future approaches Circ Heart Fail 5 2012 294 302
39. DAMOCLES Study Group A proposed charter for clinical trial data monitoring committees: helping them to do their job well Lancet 365 2005 711 722
40. S.J. Pocock Current controversies in data monitoring for clinical trials Clin Trials 3 2006 513 521
41. J.J.V. McMurray, M. Packer, A.S. Desai, et al. for the PARADIGM-HF Investigators and Committees Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 2014 993 1004
42. K. Swedberg, M. Komajda, M. Böhm, et al. for the SHIFT Investigators Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 376 2010 875 885
43. K. Fox, I. Ford, P.G. Steg, et al. for the BEAUTIFUL Investigators Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 807 816
44. V.M. Montori, P.J. Devereaux, N.J. Adhikari, and et al. Randomized trials stopped early for benefit: a systematic review JAMA 294 2005 2203 2209
45. J.M. Lachin Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit Clin Trials 6 2009 565 573
46. M.-G. Bousser, P. Amarenco, A. Chamorro, et al. for the PERFORM Study Investigators Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial Lancet 377 2011 2013 2022
47. K. Swedberg, J.B. Young, I.S. Anand, et al. for the RED-HF Investigators Treatment of anemia with darbepoetin alfa in systolic heart failure N Engl J Med 368 2013 1210 1219
48. D.L. DeMets, S.J. Pocock, and D.G. Julian The agonising negative trend in monitoring of clinical trials Lancet 354 1999 1983 1988
49. P.J. Barter, M. Caulfield, M. Eriksson, et al. for the ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
50. S.J. Connolly, A.J. Camm, J.L. Halperin, et al. for the PALLAS Investigators Dronedarone in high-risk permanent atrial fibrillation N Engl J Med 365 2011 2268 2276
51. S.H. Hohnloser, H.J.G.M. Crijns, M. van Eickels, et al. for the ATHENA Investigators Effect of dronedarone on cardiovascular events in atrial fibrillation N Engl J Med 360 2009 668 678
52. J.H. Alexander, R.D. Lopes, S. James, et al. for the APPRAISE-2 Investigators Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
53. P. Gallo, C. Chuang-Stein, V. Dragalin, et al. for the PhRMA Working Group Adaptive designs in clinical drug development - an executive summary of the PhRMA Working Group J Biopharm Stat 16 2006 275 283 discussion 285-91
54. S.C. Chow, and M. Chang Adaptive design methods in clinical trials - a review Orphanet J Rare Dis 3 2008 11
55. Committee for Medicinal Products for Human Use (CHMP). Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. European Medicines Agency. 2007. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003616.pdf. Accessed November 2, 2015.
56. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: adaptive design clinical trials for drugs and biologics. Draft guidance. 2010. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf. Accessed November 2, 2015.
57. C.R. Mehta, and S.J. Pocock Adaptive increase in sample size when interim results are promising: a practical guide with examples Stat Med 30 2011 3267 3284
58. C.U. Kunz, T. Friede, N. Parsons, and et al. Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data Pharm Stat 13 2014 238 246
59. N. Simon, and R. Simon Adaptive enrichment designs for clinical trials Biostatistics 14 2013 613 625
60. W.F. Rosenberger Randomized play-the-winner clinical trials: review and recommendations Control Clin Trials 20 1999 328 342
61. R.A. Harrington, G.W. Stone, S. McNulty, and et al. Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
62. C. Mehta, P. Gao, D.L. Bhatt, and et al. Optimizing trial design: sequential, adaptive, and enrichment strategies Circulation 119 2009 597 605
63. D.L. Bhatt, G.W. Stone, K.W. Mahaffey, et al. for the CHAMPION PHOENIX Investigators Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313